Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | EGFR | P00533 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 9/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | TGM2 | P21980 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.38 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9289784 | 1.00 | MEN1 (0.68) | MEN1KMT2ACYP1A2NPSR1EGFR | |
| SCHEMBL1398151 | 1.00 | MEN1 (0.68) | MEN1KMT2ACYP1A2NPSR1EGFR | |
| SCHEMBL1398126 | 0.88 | MEN1 (0.58) | MEN1KMT2ACYP1A2NPSR1EGFR | |
| SCHEMBL2044207 | 0.88 | MEN1 (0.58) | MEN1KMT2ACYP1A2NPSR1EGFR | |
| SCHEMBL2044203 | 0.88 | MEN1 (0.58) | MEN1KMT2ACYP1A2NPSR1EGFR | |
| SCHEMBL1398125 | 0.88 | MEN1 (0.58) | MEN1KMT2ACYP1A2NPSR1EGFR | |
| SCHEMBL15598282 | 0.84 | MEN1 (0.54) | MEN1KMT2ACYP1A2NPSR1EGFR | |
| SCHEMBL14135715 | 0.82 | MEN1 (0.65) | MEN1KMT2ACYP1A2NPSR1TP53 | |
| SCHEMBL5952677 | 0.82 | MEN1 (0.65) | MEN1KMT2ACYP1A2NPSR1TP53 | |
| SCHEMBL5952682 | 0.82 | MEN1 (0.65) | MEN1KMT2ACYP1A2NPSR1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116396204-A | Preparation method of 4,6,7-trifluoro-1H-indole-2-carboxylic acid | 无锡科华生物科技有限公司 | 2023-07-07 | — | — | CN | claimed |
| US-20240166660-A1 | KRAS G12C INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2024-05-23 | — | — | US | disclosed |
| CN-116396204-A | Preparation method of 4,6,7-trifluoro-1H-indole-2-carboxylic acid | 无锡科华生物科技有限公司 | 2023-07-07 | — | — | CN | disclosed |
| EP-1957481-B1 | PYRROLIDIN(THI)ONES HETEROCYCLICALLY SUBSTITUTED IN 3-POSITION | GRUENENTHAL GMBH (DE) | 2011-03-02 | — | — | EP | disclosed |
| US-20080293749-A1 | Pyrrolidine(thi)ones Substituted by Heterocyclic Substituents in The 3-Position | GRUENENTHAL GMBH (DE) | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240166660-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | MEN1 527/4885KMT2A 1435/4885CYP1A2 4380/4885 |
| US-20080293749-A1 | Pyrrolidine(thi)ones Substituted by Heterocyclic Substituents in The 3-Position | TPMT, MALT1, THPO | MEN1 1199/4885KMT2A 1771/4885CYP1A2 1837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.